por Sean Ruck
, Contributing Editor | June 16, 2020
From the May 2020 issue of HealthCare Business News magazine
HCB News: Other than the pandemic hurting everyone, continued shortages of Mo-99 and reimbursement issues, are there any other big challenges facing members today?
I’d call it more an opportunity — the growth of theranostics. Nuclear medicine has done theranostics since the 40s with I-131 for thyroid cancer. But the development of new agents over the past five years or so and the recent approval of several has provided a great opportunity. The challenge is to make sure that these new agents are broadly adopted. They’re very effective, but their visibility is perhaps not as high as it should be. This is one area where the Society can help a great deal, in terms of educating referring physicians and oncologists, but also educating patients about the availability and effectiveness of these new drugs.Back to HCB News
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.